Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults

The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study

(2014) Matthieu Mahévas et al.   BRITISH JOURNAL OF HAEMATOLOGY

Modified antibody in fetal alloimmunization

(2013) J. B. Bussel et al.   BLOOD

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

(2013) Francesco Rodeghiero et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists

(2013) Bahareh Ghadaki et al.   TRANSFUSION

Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

(2012) James B. Bussel et al.   BRITISH JOURNAL OF HAEMATOLOGY

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET